Research programme: oral influenza therapeutics - TSRL

Drug Profile

Research programme: oral influenza therapeutics - TSRL

Alternative Names: TSR-026; TSR-462

Latest Information Update: 26 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TSRL
  • Class Guanidines; Pyrans; Sialic acids
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 26 Jun 2014 Preclinical development is ongoing in the US
  • 26 Jun 2014 Oral influenza therapeutics - TSRL is available for licensing (www.tsrlinc.com)
  • 26 Oct 2012 TSRL reaches an agreement with the US FDA on preclinical and clinical development strategy for TSR 026
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top